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The Association Between Reactive Oxygen Metabolites and 
Metabolic Syndrome in Asymptomatic Japanese Men
Kazuhiko Kotania, b, Nobuyuki Taniguchia
Abstract
Background: The association between the oxidative status and 
metabolic syndrome (MetS) should be studied in various popula-
tions with various oxidative stress-related markers. The aim of this 
cross-sectional study was to investigate the association between 
oxidative status, as assessed by the reactive oxygen metabolites (d-
ROMs) test, and MetS in asymptomatic Japanese men, in relation 
to age.
Methods: The serum d-ROMs levels were measured in cardiovas-
cular disease-free, non-smoking, non-medicated males (n = 140), 
who were divided into groups as follows: Group 1, < 60 years (n = 
75, mean age 46 ± 9 [SD] years), and Group 2, ≥ 60 years (n = 65, 
mean 68 ± 6 years). The MetS was determined by the NCEP-ATP 
recommendations with minor modiﬁ  cations for a Japanese popula-
tion.
Results: There was no signiﬁ  cant difference in the d-ROMs lev-
els between the subjects with and without MetS in Group 2 (≥ 60 
years), but the subjects with MetS (n = 38, 324 ± 59 U. Curr.) ex-
hibited signiﬁ  cantly higher d-ROMs levels than those without MetS 
(n = 37, 290 ± 49 U. Curr., P < 0.01) in Group 1 (< 60 years). 
These differences did not change even after adjustments for basic 
confounders.
Conclusions: These results suggest that oxidative status, as as-
sessed by the d-ROMs, can be enhanced among asymptomatic 
younger, but not older, Japanese males with MetS. Further studies 
are required to establish the observed associations.
Keywords: Oxidative stress; Reactive oxygen species; D-ROMs; 
Obesity; Metabolic syndrome
Introduction
When cardiometabolic risk factors such as obesity, hypergly-
cemia, dyslipidemia and hypertension are clustered, cardio-
vascular disease (CVD) risks are remarkably increased [1]. 
While metabolic syndrome (MetS) represents a clustering 
disorder of such risk factors, a deeper understanding of the 
underlying mechanisms of the contribution of MetS to CVD 
is needed to control CVD events [2]. One of the major patho-
physiologies of MetS is an oxidative condition caused by the 
overproduction and inactivation of reactive oxygen species 
(ROS) [3]. Although numerous studies have examined oxi-
dative status in MetS subjects using oxidative stress-related 
markers, these results are not always consistent [4-12]. This 
can partly be due to differences in not only the studied popu-
lations but also in the markers used; namely, we note the 
weaker associations in healthier relative to diseased popula-
tions [4, 7, 11] and a different signiﬁ  cance of markers used 
on MetS traits is reported even in the same population [10]. 
Recently, the reactive oxygen metabolites (d-ROMs, Dia-
cron, Italy) test was developed to quantify oxidative status 
by measuring the hydroperoxidation of organic compounds 
(occurring in lipids, proteins, nucleic acids, etc.) [13, 14], 
and is also used in medical settings [15-17]. However, the 
literature on determining oxidative status using this test in 
MetS subjects is rare.
Another debatable point is a difference in the clinical 
relevance of MetS on CVD between genders and age; name-
ly, there may be a higher CVD risk in men with MetS than 
women [18] and minimal MetS-CVD linkage in relatively 
older populations [12, 19, 20]. Therefore, the aim of this 
study was to investigate the association between the levels of 
d-ROMs and MetS properties in an asymptomatic Japanese 
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male population, in considering different age groups.
Methods
A total of 140 non-smoking, non-medicated male partici-
pants were recruited during routine check-ups in health edu-
cation classes and outpatient clinics. This population was di-
vided into two groups by age: Group 1, < 60 years of age and 
Group 2, ≥ 60 years of age (Table 1). Eligible subjects had 
no histories of cardiovascular, thyroid, hematological, renal, 
hepatic, or collagenous diseases. The presence of MetS was 
diagnosed with at least 3 out of 5 of the following criteria 
according to the National Cholesterol Education Program 
Adult Treatment Panel (NCEP-ATP) III recommendations 
[2]: 1) obesity identiﬁ  ed by body mass index (BMI) ≥ 25.0 
kg/m2 as a surrogate for a Japanese population [21]; 2) in-
creased blood pressure (BP) identiﬁ  ed by systolic BP (SBP) 
≥ 130 mmHg and/or diastolic BP (DBP) ≥ 85 mmHg; 3) 
hypertriglyceridemia identiﬁ  ed by serum triglyceride (TG) 
≥ 1.69 mmol/L; 4) low high-density lipoprotein cholesterol 
(HDL-C) identiﬁ  ed by serum HDL-C < 1.04 mmol/L, and 5) 
hyperglycemic status identiﬁ  ed by a fasting plasma glucose 
(FPG) ≥ 6.1 mmol/L. The study was approved by the institu-
tional ethics committee, and all subjects gave their informed 
consent.
In addition to BMI, the SBP and DBP levels were de-
termined in the seated subject’s right-arm with a mercury 
sphygmomanometer. Blood was sampled after an overnight 
fast with no alcohol consumption or exercise during the pre-
ceding day. The serum TG and FPG levels were measured 
using enzymatic methods, and the serum low-density lipo-
protein (LDL-C) and HDL-C levels were measured using 
homogeneous methods (Sekisui Co. Ltd., Tokyo, Japan). 
The d-ROMs values were obtained using a kinetic spectro-
photometric assay (F.R.E.E system; Diacron, Italy) with the 
intra- and inter-assay coefﬁ  cients of variation of 2.1% and 
3.1%, respectively [13, 14]. Brieﬂ  y, serum samples were 
mixed with a buffered solution, and a chromogenic substrate 
was added into the mixture. The mixture was centrifuged and 
then incubated in the thermostatic block of the system. The 
absorbance was then recorded at 505 nm. Measurements are 
expressed as U. Carr., and 1 U. Carr. corresponds to 0.08 
mg/dL H2O2 (the reference value is suggested to be approxi-
mately 250 - 300 U. Carr.).
Data are expressed as the means ± SD or medians plus 
interquartile range. Differences between two groups were 
analyzed using the unpaired t-test. The inﬂ  uence of MetS (as 
a ﬁ  xed variable) on d-ROMs (as a dependent variable) was 
examined using a general linear model analysis with adjust-
ments for basic confounders (i.e., age or LDL-C that is not 
included in the diagnostic criteria of MetS but can contribute 
to the development of CVD and oxidative status). The values 
of TG were log-transformed for the analyses because of the 
skewed distribution. A P-value of < 0.05 was considered to 
be statistically signiﬁ  cant.
Results
The clinical characteristics between age-stratiﬁ  ed groups are 
shown in Table 1. Group 2 (≥ 60 years) showed signiﬁ  cantly 
higher age and SBP levels and a lower BMI level than Group 
1 (< 60 years). Although Group 2 had high FPG and d-ROMs 
levels relative to Group 1, these differences did not reach 
statistically signiﬁ  cant levels.
The prevalence of MetS was 51% and 57% in Groups 1 
and 2, respectively, as shown in Table 2. There were no sig-
Table 1. Clinical Characteristics Between Groups 1 (< 60 Years) and 2 (≥ 60 Years)
Variable Group 1 (n = 75) Group 2 (n = 65) P-value
Age (years) 46 ± 9 68 ± 6 < 0.01**
Body mass index (kg/m2) 25.6 ± 3.6 24.0 ± 2.9 < 0.01**
Systolic BP (mmHg) 135 ± 19 147 ± 23 < 0.01**
Diastolic BP (mmHg)  83 ± 12 82 ± 11 0.84
Glucose (mmol/L)  6.71 ± 2.54 7.25 ± 2.48 0.21
LDL-cholesterol (mmol/L)  3.85 ± 1.40 3.75 ± 0.79 0.58
Triglycerides (mmol/L) 1.84 (1.40 - 3.62) 1.99 (1.32 - 2.64) 0.14
HDL-cholesterol (mmol/L)  1.42 ± 0.42 1.44 ± 0.37 0.80
D-ROMs (U. Carr.) 307 ± 57 327 ± 65 0.06
BP, blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; d-ROMs, reactive oxygen 
metabolites. Statistical signiﬁ  cance (by unpaired t-test between Groups 1 and 2): ** P < 0.01.
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niﬁ  cant differences in the d-ROMs levels between each crite-
rion of MetS in either group (Table 2). However, while there 
was no signiﬁ  cant difference in the d-ROMs levels between 
the subjects with and without MetS in Group 2 (P = 0.26), the 
subjects with MetS exhibited a signiﬁ  cantly higher d-ROMs 
level than those without MetS in Group 1 (P < 0.01). The dif-
ference in the d-ROMs levels by MetS remained statistically 
signiﬁ  cant, even after adjusting for age (F = 7.46, P < 0.01) 
and for age and LDL-C (F = 11.11, P < 0.01).
Discussion
  
The present study revealed a signiﬁ  cantly higher d-ROMs 
level in Japanese male subjects with MetS than those without 
MetS in Group 1 (< 60 years), but not Group 2 (≥ 60 years). 
It would therefore be valuable to add new ﬁ  ndings to our cur-
rent knowledge regarding the association between MetS and 
oxidative status, by using the d-ROMs test that differed from 
the test described in previous studies [4-12].
The ﬁ  rst notable ﬁ  nding of this study is conﬁ  rmation 
that, although no signiﬁ  cant differences in the d-ROMs levels 
were observed between each criterion of MetS, MetS clearly 
expressed the hyperoxidative status of the d-ROMs. This is 
in agreement with the clustering concept of MetS (a disorder 
clustering of each criterion) to remarkably increase the CVD 
risks [1, 2]. Fat and systemic ROS, which stem from obese 
adipocytes and unfavorable lifestyles, are associated with 
the augmentation of NADPH-oxidase and suppression of 
antioxidative enzymes, and these pathways can directly lead 
to the initiation/development of MetS via cell damage and 
indirectly via dysregulated adipocytokines [3, 22]. The pro-
gression/exacerbation of the MetS critera further promotes a 
vicious circle with the addition of oxidative stress induced 
at atherosclerotic sites [3]. The biological mechanisms can 
account for the present ﬁ  nding of a signiﬁ  cant increase of 
the d-ROMs levels in MetS subjects. In addition, although 
the previous studies suggested a signiﬁ  cant increase of the 
d-ROMs in hypertensive subjects [15] and obese subjects 
[17], weak differences in the d-ROMs between solo criterion 
groups observed in the present study might partially be ex-
plained by the differences in studied populations (the present 
study population was of a relatively good state and/or mild 
state, even though the subjects showed the diseased levels, 
as seen in Table 1).
The second notable ﬁ  nding of this study is conﬁ  rmation 
that a signiﬁ  cant increase of the d-ROMs levels in MetS was 
clearly observed in the younger Group 1, rather than the old-
er Group 2. Previous studies indicated weak magnitudes of 
MetS on CVD in elderly populations [19, 20], while another 
study reported a signiﬁ  cant positive relationship between 
MetS and oxidative status in an elderly population [12]. Al-
though the precise reasons for these ﬁ  ndings remain to be 
unclear, our present study seems to support the former stud-
ies [19, 20]. Because aging per se is an oxidative condition 
(in fact, Group 2 tended to show somewhat high d-ROMs 
levels relative to Group 1, as seen in Table 1) [23], it may 
be difﬁ  cult or confusing to distinguish clearly the oxidative 
Table 2. Comparative Data on the d-ROMs Levels Between the Absence and Presence of Metabolic Syndrome 
and its Criteria in Groups 1 (< 60 Years) and 2 (≥ 60 Years)
Comparative Data on the d-ROMs Levels Between the Absence and Presence of Metabolic Syndrome and its 
Criteria in Groups 1 (< 60 Years) and 2 (≥ 60 Years)
d-ROMs, reactive oxygen metabolites; BP, blood pressure; HDL, high-density lipoprotein. Statistical signiﬁ  cance 
(by unpaired t-test between the absence and presence of metabolic syndrome and its criteria in Groups 1 and 
2): ** P < 0.01.
Criteria
Group 1 (n = 75) Group 2 (n = 65)
absence (n) presence (n) absence (n) presence (n)
Obesity 298 ± 59 (36) 316 ± 53 (39) 330 ± 72 (40) 323 ± 52 (25)
Increased BP 304 ± 56 (26) 309 ± 57 (49) 302 ± 58 (13) 333 ± 65 (52)
Hyperglycemia 306 ± 63 (47) 308 ± 44 (28) 317 ± 56 (26) 334 ± 70 (39)
Hypertriglyceridemia 297 ± 47 (25) 312 ± 60 (50) 322 ± 68 (26) 331 ± 63 (39)
Hypo-HDL-cholesterolemia 304 ± 54 (67) 336 ± 74 (8) 329 ± 65 (60) 301 ± 56 (5)
Metabolic syndrome 290 ± 49 (37) 324 ± 59 (38)** 317 ± 69 (28) 335 ± 60 (37)
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status between pathologies in older subjects. This seems to 
be an important view to control MetS-related CVD events, if 
the potential magnitudes of MetS on CVD can differ by age. 
The possibility that the inﬂ  uence of MetS on CVD can be 
modulated by age merits further investigations.
The present study had a few limitations. The cross-sec-
tional design did not allow for determining the cause-and-
effect relationship. The study was conducted in male par-
ticipants only and in relatively small sample sizes. Future 
studies with larger populations including females and pro-
spective/interventional designs are needed.
In summary, the present study showed signiﬁ  cantly 
higher d-ROMs levels in asymptomatic Japanese male sub-
jects with MetS than those without MetS in Group 1 (< 60 
years), but not Group 2 (≥ 60 years). The oxidative status 
can be enhanced under the clustering concept of MetS in 
younger men in particular, which may imply an age-modu-
lated effect of MetS on CVD. Further studies are necessary 
to establish the observed associations.
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